SuperworthRecursion Pharmaceuticals market cap RXRX
Share price times shares outstanding: what the whole company sells for, since 2021.
- Today, Oct 23, 2026
- $2B
- Highest close in our data
- $6.8B
- Jul 2021
Recursion Pharmaceuticals is worth $2B at the close on Oct 23, 2026, at $3.70 a share.
That is down 24% over the last year and down 39% over five years.
Its highest close in our data was $6.8B in Jul 2021.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $2B | $1.6B | $2.5B | −10% |
| 2025 | $2.2B | $1.7B | $3B | +4% |
| 2024 | $2.1B | $1.6B | $3B | −1% |
| 2023 | $2.1B | $912.2M | $3B | +46% |
| 2022 | $1.5B | $930.6M | $2.7B | −50% |
| 2021 | $2.9B | $2.8B | $6.8B | n/a |
Against its peers
Companies in Biotechnology nearest Recursion Pharmaceuticals' size, closest first, today.
| Company | Market cap |
|---|---|
| RXRXRecursion Pharmaceuticals | $2B |
| VCELVericel | $2.2B |
| ADMAAdma Biologics | $2.4B |
| MGTXMeiraGTx | $884.6M |
| KRYSKrystal Biotech | $9.2B |
| RGENRepligen | $10B |
| TECHBIO-TECHNE | $11.4B |
| HALOHalozyme Therapeutics | $14.3B |
| NBIXNeurocrine Biosciences | $14.5B |
| EXELExelixis | $16B |
| PLXProtalix BioTherapeutics | $205.5M |
| Peer median | $9.6B |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Recursion Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.